From: NIH Research Matters <nih.ocpl@service.govdelivery.com>
Date: Mon, Aug 25, 2014 at 11:12 AM
Subject: Malaria treatment, chikungunya vaccine, and glutamate receptor structure
To: iammejtm@gmail.com
A combination drug treatment substantially reduced malaria in young children in Africa. The treatment could help reduce the disease burden among those most at risk.
A chikungunya vaccine gave encouraging results in an early-stage clinical trial. A vaccine could prevent outbreaks of the disease, which recently reached the U.S. mainland.
Scientists determined the detailed structural states of the glutamate receptor, which is involved in learning, memory, and several diseases.
Popular Stories from past issues:
NIH Research Matters is also available as an RSS News Feed. Point your RSS reader to http://www.nih.gov/researchmatters/feed.xml (to learn more about RSS, visit http://www.nih.gov/news/rss.htm).
Update Your E-mail Address | Add Subscriptions | Unsubscribe If you have questions or problems with the subscription service, please visit subscriberhelp.govdelivery.com. For all other inquiries about NIH programs and activities, please contact NIHinfo@od.nih.gov. Before writing, please view our Frequently Asked Questions page, our A-Z Health Topics page, or Search our website. This service is provided to you by the National Institutes of Health.
|
Jeremy Tobias Matthews
No comments:
Post a Comment